Assessment of acquired hemophilia patient demographics in the United States: the Hemostasis and Thrombosis Research Society Registry by Kessler, Craig M. et al.
Original article 761
0957-5235 Copyrig
This is an open-acce
download and shareent of acquired hemoAssessm philia patient demographics in
the United States: the Hemostasis and Thrombosis Research
Society Registry
Craig M. Kesslera, Alice D. Mab, Hamid A.B. Al-Mondhiryc, Robert Z. Gutd
and David L. CooperdThe Hemostasis and Thrombosis Research Society (HTRS)
Registry was used to monitor the postapproval use of
recombinant factor VIIa. The objective of this manuscript is
to provide key insights on the demographics of patients with
acquired hemophilia in the HTRS Registry. Acquired
hemophilia patient registration in HTRS captured age; sex;
comorbidities and predisposing conditions; first bleeding
location; laboratory parameters; exposure to blood
products, factor, and bypassing agents; and initiation of
immune suppression/tolerance therapy. Overall, 166
patients with acquired hemophilia were registered in HTRS
(83 women, 73 men, median age 70 years); the majority
were non-Hispanic whites (61.4%). The most common
comorbidities were autoimmune disease (28.4%) and
malignancy (14.5%). The most common first site of bleeding
was subcutaneous (27.1%); this was more common in
whites (29.1%) than blacks (12.5%) and in non-Hispanics
(26.4%) than Hispanics (11.8%). Blood product exposure
was reported for 33.1% of patients; the most commonly
reported product was packed red blood cells (28%). Of the
57 patients with outcome data available for immune
tolerance therapy, 26 patients (46%) reported successful
treatment, 13 reported unsuccessful treatment (23%), and
18 (32%) were receiving active treatment at the time of
registration. The HTRS Registry final analysis provides theht  2016 Wolters Kluwer Health, Inc. All rights reserved.
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the US population, including details on underlying
autoimmune diseases and malignancies. Pertinent to
recognition and diagnosis of the disease, subcutaneous
bleeding as a presenting bleeding symptom was more
common in white and non-Hispanic individuals. Blood
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Acquired hemophilia is a rare disorder marked by the
development of autoantibodies to factor VIII (FVIII).
Patients present with bleeding and a prolonged activated
partial thromboplastin time (aPTT) that does not correct
with prolonged incubation mixing with normal plasma
(2 h, 378C).
The first insights into the demographics of acquired hemo-
philia in the United States were provided in the initial
findings by Green and Lechner [1] (215 patients) and
showed bimodal distribution around age, with a small peak
seen from age 21 to 30 years that correlates with mostly
younger patients with postpartum hemorrhage (8.0% of all
patients) and a larger peak for older men and women in
relatively equal proportions. Nearly half of all patients
were aged at least 61 years (61–70 years: 24.5% and 71–80
years: 23.9%). Subsequent findings in the United King-
dom, including a surveillance study through the United
Kingdom Haemophilia Centre Doctors’ Organisation
(UKHCDO, 172 patients) [2] and a prospective surveyof hematologists in south and west Wales (18 patients) [3],
have provided more recent data on acquired hemophilia
within a national health system with a referral paradigm
that assured nearly complete case identification and con-
firmed that the incidence of acquired hemophilia is
roughly 1.3–1.5 per million [4] and that incidence
increases with age. Of the 172 patients in the UKHCDO
data set, 63% were aged 65 to less than 85 years and an
additional 22% were aged at least 85 years. Most recently,
the European Acquired Hemophilia Registry (EACH2)
provided additional insights on 501 patients with acquired
hemophilia from 117 different hemophilia treatment cen-
ters in 13 European countries. As seen in other studies, age
had a bimodal distribution, with a small peak occurring in
younger women with peripartum acquired hemophilia
(median age 33.9 years) [5].
Acquired hemophilia is associated with a wide variety
of underlying conditions, such as lymphoproliferative
or myeloproliferative disorders, solid tumors, auto-
immune diseases, drugs (e.g. penicillin, chloramphenicol,DOI:10.1097/MBC.0000000000000582
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allogeneic bone marrow transplantation. Acquired hemo-
philia is also known to occur during the postpartum
period up to several months after delivery; it was seen
in 2% of patients in UKHCDO (acquired hemophilia
was pregnancy related in three of four patients aged 21–
40 years, and occurred at day 1, week 8, and month
7 postpartum) and in 42 (8.4%) patients in EACH2
who were diagnosed between 21 and 120 days following
delivery [2,5,6].
The Hemostasis and Thrombosis Research Society
(HTRS) Registry was established in 1999 as a joint effort
of the then Hemophilia Research Society (HRS) and
Novo Nordisk Inc. The registry’s purpose was to serve
as a platform for society-based research on bleeding
disorders and to monitor the postapproval use of recom-
binant factor VIIa (rFVIIa, NovoSeven, Novo Nordisk
A/S, Bagsvaerd, Denmark). Since rFVIIa was approved in
2006 by the US Food and Drug Administration for the
additional indication of treatment of bleeding and pre-
vention of bleeding during surgical procedures in patients
with acquired hemophilia, the HTRS Registry has been
used for postmarketing surveillance. This article aims to
provide key insights on the demographics of acquired
hemophilia in the United States based on the HTRS
Registry, with specific focus on assessing differences in
presentation across sex, race, and ethnicity.
Methods
This was a retrospective review of data from the HTRS
Registry, a longitudinal database capturing the demo-
graphics and treatment of bleeding episodes and surgery
in patients with bleeding disorders. Originally named for
the then HRS, the registry was renamed along with the
society’s name change to HTRS in 2004 and upgraded on
a regular basis to include specific questions relating to
acquired hemophilia and consolidated demographic data
from the HRS and HTRS registries.
Institutional Review Board approval to participate was
obtained by all sites, with either patient informed consent
obtained prior to patient data entry or Institutional
Review Board exemption of consent for retrospective
collection of anonymized data. Registration and follow-
up data on patients with bleeding disorders were sub-
mitted voluntarily by hemophilia treatment centers in the
United States and one center in Quebec. Registration
forms for patients with acquired hemophilia captured
age; sex; comorbidities and predisposing conditions; first
bleeding location; laboratory parameters; exposure to
blood products, factor, or bypassing agents; and initiation
of immune suppression/tolerance. Active prompts for
adverse events (i.e. ‘yes’ or ‘no’) on all data entry forms
and screens were provided as mandatory affirmation
fields to ensure adverse event reporting; mortality and
status change forms were completed as needed.This retrospective analysis examined all patients regis-
tered between January 2000 and December 2011 with a
reported diagnosis of acquired hemophilia, regardless of
whether bleeding episodes or surgical procedures were
documented. Statistical analyses were performed on the
SAS data set by Quintiles Outcome by Quintiles Inc.
(formerly Outcome Sciences) of Cambridge, Massachu-
setts, USA, the contract research organization that man-
aged the registry. Further descriptive subanalyses by sex,
race, and ethnicity were performed by the authors.
Results
Patient disposition and demographics
Between 2000 and 2011, 36 of approximately 100 maxi-
mum HTRS sites submitted acquired hemophilia patient
cases, with a mean/median (range) of 4.6/3 (1–22) cases
per site. A total of 166 patients were registered in the
HRS Registry (21 patients, 14 with bleed records; 2000–
2003) and HTRS Registry (145 patients, 116 with bleed
or surgery records; 2004–2011) databases. The demo-
graphics of those entered in the HRS and HTRS regis-
tries and those with and without bleeding records were
similar; therefore, they are presented as composite data in
Table 1.
Overall, 83 female and 73 male patients were registered
with a mean/median age of 65.3/70 years; for 10 patients
(6.0%), sex was not recorded. The mean/median ages
were similar for male and female patients (Fig. 1a), white
and black patients (Fig. 1b), and non-Hispanic/Hispanic
patients (Fig. 1c). The majority of registered patients
(n¼ 119, 72%) were aged 61–92 years and were non-
Hispanic whites (n¼ 102, 61.4%). However, nearly 25%
(40/166) were black. Most patients (n¼ 51, 30.7%) had
unrestricted functional status at registration, full school or
work functional status with limited recreation (n¼ 11,
6.6%), or limited school, work, or activities (n¼ 59,
35.5%) as defined by the five-category scale in the Uni-
versal Data Collection System (Annual Visit Form Ques-
tion 34. CDC 59.8C 10/2005) [7]. The median (range)
highest human anti-FVIII titer was 50 (1–2969) Bethesda
units. The median (range) highest porcine anti-FVIII
titer was 2.2 (0–20) Bethesda units.
Comorbidities
Comorbidities were recorded for 145 patients with
acquired hemophilia in the HTRS Registry. General
categories and common subcategories were provided,
as were ‘other’ fields for free-text entry. The most fre-
quently recorded illnesses were autoimmune disease
(n¼ 41, 28.4%) and malignancy (n¼ 21, 14.5%). Other
comorbidities included surgery/intervention (11.7%),
postpartum hemorrhage (PPH) (3.4%), trauma (1.4%),
other (15.9%), and not specified (44.1%) (Tables 2 and 3).
Of 41 patients with reported autoimmune diseases,
16 were reported to have diabetes mellitus (type 2 or
unspecified) entered as ‘other’ autoimmune disease.
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Table 1 Summary of patient demographics Hemostasis and Thrombosis Research Society Registry: Demographics
HRS patients HTRS patients
A B C D
Registration only With bleed records Registration only With bleed/surgery records
Number of patients 7 14 29 116
Age at registration (years)
Mean (SD) 56 (15.82) 63 (14.60) 61 (22.11) 67 (16.81)
Median (range) 59 (36–78) 64 (22–80) 68 (13–88) 73 (13–92)
Sex, n (%)
Male 0 (0.00) 1 (7.14) 12 (41.38) 60 (51.72)
Female 7 (100.00) 3 (21.43) 17 (58.62) 56 (48.28)
Missing 0 (0.00) 10 (71.43) 0 (0.00) 0 (0.00)
Ethnicity, n (%)
White, non-Hispanic 3 (42.86) 8 (57.14) 13 (44.83) 78 (67.24)
White, Hispanic 1 (14.29) 3 (21.43) 4 (13.79) 7 (7.37)
Black, non-Hispanic 1 (14.29) 2 (14.29) 9 (31.03) 26 (22.41)
Black, Hispanic 0 (0.00) 0 (0.00) 1 (3.45) 1 (0.86)
Unknown 1 (14.29) 1 (7.14) 1 (3.45) 2 (1.72)
Other 1 (14.29) 0 (0.00) 1 (3.45) 2 (1.72)
Functional status at registration, n (%)
Unrestricted 4 (57.14) 3 (21.43) 14 (48.28) 30 (25.86)
Full school/work, limited recreation 0 (0.00) 0 (0.00) 1 (3.45) 10 (8.62)
Limited school/work/activities 0 (0.00) 1 (7.14) 9 (31.03) 49 (42.24)
Requires assistance, no recreation 0 (0.00) 0 (0.00) 4 (13.79) 23 (19.83)
Unknown 3 (42.86) 10 (71.43) 1 (3.45) 4 (3.45)
Inhibitor titers (BU)
Highest human, anti-VIII
Mean 168.24 59.90 156.20 202.29
Median (range) 61.0 (9.7–665) 22.0 (3–220) 64.0 (6.8–960) 48.0 (1–2969)
Lowest human, anti-VIII
Mean 0.83 3.54 48.04 45.17
Median (range) 0.00 (0–4) 1.00 (0–18.9) 0.00 (0–520) 2.00 (0–878.1)
Current human, anti-VIII
Mean ND ND 15.90 60.30
Median (range) ND ND 0.00 (0–118) 5.15 (0–878.1)
Highest porcine, anti-VIII
Mean 5.50 5.71 ND 2.80
Median (range) 5.50 (0–11) 2.00 (0–20) ND 2.25 (0–6.5)
Lowest porcine, anti-VIII
Mean 0.00 0.50 ND 0.73
Median (range) 0.00 (0–0) 0.00 (0–5) ND 0.30 (0–2.3)
BU, Bethesda units; HRS, Hemophilia Research Society; HTRS, Hemostasis and Thrombosis Research Society; ND, no data; SD, standard deviation.Excluding 14 patients who reported diabetes only,
27 (18.6%) reported other autoimmune disorders, the
most common of which were rheumatoid arthritis
(n¼ 10), systemic lupus erythematosus (n¼ 4), and bul-
lous pemphigoid (n¼ 3) (Table 3). Autoimmune occur-
rence was similar across sex and race, but was higher in
women (32 vs. 22% in men) and non-Hispanics (29 vs. 8%
in Hispanics). This difference held true for autoimmune
diseases other than diabetes.
Malignancy occurrence was similar across sex and race,
but was higher in non-Hispanics (16 vs. 0% in Hispanics).
The most common malignancies reported were breast
cancer (six cases), leukemia (three cases, two of which
were known by the authors to be chronic lymphocytic
leukemia), and prostate cancer (three cases, one of which
was reported to be metastatic). Two cases each of blad-
der, gastrointestinal (including intestine, stomach, eso-
phagus, colon, or rectum), and cervical cancer were
reported in the registry. Two cases of myeloproliferative
neoplasms (polycythemia vera and myelofibrosis) were
reported as ‘other disorders’ but were included in thisanalysis as malignancies to reflect current understanding
of the diseases.
The reported surgery types varied; the dates of surgery
and the surgery’s relationship to a diagnosis of acquired
hemophilia were not uniformly captured in the registry.
Type and locations of bleeds
Frequently recorded bleeding locations included the
subcutaneous area (27.1%) and mucosa (21.1%). Other
locations of the first bleeding episode for each patient
included ‘extremity not otherwise specified (NOS)’
(7.2%), muscle (5.4%), joint (4.2%), retroperitoneal
(2.4%), surgery/procedure site (1.8%), postpartum
(1.8, 3.6% women), head (1.8%), other (4.2%), and ‘not
specified’ (16.3%) (Table 4).
Subcutaneous bleeding was more common in women
(30.1%) than men (20.5%), in whites (29.1%) than blacks
(12.5%), and in non-Hispanics (26.4%) than Hispanics
(11.8%). Subcutaneous bleeding and ‘extremity NOS’
were not reported in the same patients. If ‘extremity
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Table 2 Distribution of comorbidities by sex, race, and ethnicity
All Female Male
Number of patients, n 145 73 72
Comorbidities, n (%)
Autoimmune 41 (28.3%) 24 (32.9%) 17 (23.6
Excluding diabetes 27 (18.6%) 19 (26.0%) 8 (11.1%
Diabetes only 7 (4.8%) 3 (4.1%) 4 (5.6%
Diabetes type 2 only 7 (4.8%) 2 (2.7%) 5 (6.9%
Malignancy 21 (14.5%) 10 (13.7%) 11 (15.3
Postpartum 5 (3.4%) 5 (6.8%) NA
Surgery/procedure/PICC/IV 17 (11.7%) 8 (11.0%) 9 (12.5%
Trauma 2 (1.4%) 2 (2.7%) 0 (0.0%
Other 23 (15.9%) 12 (16.4%) 11 (15.3
None specified 64 (44.1%) 28 (38.4%) 36 (50.0
IV, intravenous; NA, not applicable; PICC, peripherally inserted central catheters.NOS’ is considered an alternate potential classification of
subcutaneous bleeding locations, then the aggregate of
possible subcutaneous bleeding rises to about one-third
of patients and remains more common in white and non-
Hispanic individuals (Table 4).
Blood component exposure
Coagulation factor and hemostatic agent exposure were
recorded for on-demand and prophylactic therapies for
patients with acquired hemophilia in the HRS and HTRS
Registry platforms (Table 5). Of the 145 patients for
whom information about exposure to blood products
was reported, only 48 (33.1%) have actually received
blood products. Patient exposure included packed red
blood cells (RBCs) (28%), whole blood or fresh frozen
plasma (FFP) (14%), platelets (3%), and cryoprecipitate
(1%). FVIII exposure was reported for eight (7%) of 128
patients in whom FVIII exposure history was known and
for one of 129 patients in whom factor IX exposure history
was known (Table 5). Duration of product exposure
(in days) was reported for many products but was esti-
mated in at least half of the patients. Although the
reported use of packed RBC transfusions was similar
across race and ethnicity, the use of whole blood or
FFP and the mean/median exposure days was higher
in black than white patients and higher in Hispanic than
non-Hispanic patients. Whole blood is not readily avail-
able in the United States and likely accounts for the use
of FFP. Hemostatic products included two different
plasma-derived activated prothrombin complex concen-
trates commercially available in the United States at the
time, as well as rFVIIa, aminocaproic acid, desmopressin
acetate, antihemophilic factor, and other products.
Immune tolerance, immunosuppressive therapy, and
eradication of the auto-factor VIII antibody inhibitor
The registration case report form (CRF) was designed
originally for congenital hemophilia, and it requested
history and outcome from immune tolerance therapy
(ITT) with FVIII infusions; there were no specific ques-
tions about immunosuppression. This series of questions
was completed for 65 (39%) of 166 registered patientsWhite Black Non-Hispanic Hispanic
102 37 126 13
%) 28 (27.5%) 11 (29.7%) 38 (30.2%) 1 (7.7%)
) 20 (19.6%) 5 (13.5%) 24 (19.0%) 1 (7.7%)
) 3 (2.9%) 4 (10.8%) 7 (5.6%) 0 (0.0%)
) 5 (4.9%) 2 (5.4%) 7 (5.65%) 0 (0.0%)
%) 18 (17.6%) 3 (8.1%) 20 (15.9%) 1 (7.7%)
5 (4.9%) 0 (0.0%) 4 (3.2%) 1 (7.7%)
) 14 (13.7%) 3 (8.1%) 16 (12.7%) 1 (7.7%)
) 2 (2.0%) 0 (0.0%) 2 (1.6%) 0 (0.0%)
%) 15 (14.7%) 8 (21.6%) 21 (16.7%) 2 (15.4%)
%) 42 (41.2%) 18 (48.6%) 53 (42.1%) 7 (53.8%)
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Table 3 Detailed listing of comorbidities
Type Concomitant illness N %
Autoimmune Diabetes mellitus 16 11.0
Diabetes mellitus type 2 7 4.8
Rheumatoid arthritis 10 6.9
Systemic lupus erythematosus 4 2.8
Bullous pemphigoid 3 2.1
Autoimmune thyroiditis 2 1.4
Retroperitoneal fibrosis 1 0.7
Psoriatic arthritis 1 0.7
Multiple sclerosis 1 0.7
Lupus anticoagulant 1 0.7
Erythema nodosum 1 0.7
Chronic thrombocytopenia 1 0.7
Celiac disease 1 0.7
Autoimmune hemolytic anemia 1 0.7
Any autoimmune 41 28.3
Any autoimmune (excluding diabetes) 27 18.6
Malignancy Breast cancer 6 4.1
Leukemia 3 2.1
Prostate cancer 3 2.1
Known metastatic site 1 0.7
Bladder cancer 2 1.4
Carcinoma of the intestine, stomach,
esophagus, colon, or rectum
2 1.4
Cervix cancer 2 1.4
Liver carcinoma 1 0.7
Multicentric Castleman disease 1 0.7
Myelofibrosis 1 0.7
Polycythemia vera 1 0.7
Squamous cell left hand cancer 1 0.7
Squamous cell of face 1 0.7
Total malignancy 21 14.5
Surgery Unspecified 8 5.5
Endarterectomy 2 1.4
Appendectomy 1 0.7
Cesarean section 1 0.7
Circumcision 1 0.7
Hernia repair 1 0.7
Ileal conduit 1 0.7
Left hip replacement 1 0.7
Mediport 1 0.7
Skin graft from left leg to left elbow 1 0.7
Tonsillectomy 1 0.7
Ventral hernia repair 1 0.7
Total surgery 12 8.3
Postpartum PPH 5 3.4
Total postpartum 5 3.4
Other Hypertension 7 4.8
Chronic obstructive pulmonary disease 3 2.1
Hyperlipidemia 3 2.1
Coronary artery disease 2 1.4
Cerebrovascular accident 2 1.4
Hepatitis C 2 1.4
Herpes zoster 2 1.4
HIV 2 1.4
Peripheral vascular disease 2 1.4
Atrial fibrillation 1 0.7
Anemia 1 0.7
Anticardiolipin antibody 1 0.7
Aortic aneurysm 1 0.7




Colon perforation 1 0.7
Chronic renal failure 1 0.7
Emphysema 1 0.7






Hematoma left leg 1 0.7
Hypertension 1 0.7
Hyperthyroidism 1 0.7
Table 3 (continued )
Type Concomitant illness N %
Hypothyroidism 1 0.7
Increased cholesterol 1 0.7
Left elbow injury 1 0.7
Monoclonal gammopathy of
undetermined significance (not cause
of inhibitor)
1 0.7




Paroxysmal nocturnal hemoglobinuria 1 0.7
Pneumonia 1 0.7
Polymyalgia rheumatica 1 0.7
Pulmonary nodule not biopsied 1 0.7
s/p OVA 1 0.7
Transient ischemic attack 1 0.7
CABG, coronary artery bypass grafting; GERD, gastroesophageal reflux disease;
PPH, postpartum hemorrhage.with acquired hemophilia. It is unlikely that the individ-
ual hemophilia center physicians applied immune
tolerance regimens in a uniform manner for all the
patients in this study analysis. Furthermore, it is difficult
to determine if in all cases the physician’s use of immu-
nosuppressive therapy was intended to be included as a
component of an immune tolerance protocol or simply as
an immune system modulator to eradicate the inhibitory
antibody. More detailed ITT/immune suppression CRFs
were available but were not completed for most regis-
tered patients with acquired hemophilia.
Of the 57 evaluable patients with outcome data,
26 patients (46%) reported successful ITT treatment,
13 reported unsuccessful ITT treatment (23%), and
18 (32%) were receiving active treatment at the time
of registration.
Discussion
Acquired hemophilia is a very rare disease, occurring in
only one in 1 million individuals [1]. Presumably, the
300–350 US patients who develop autoantibodies each
year could present acutely to approximately 5700 hospi-
tals [8] and a variety of specialists [9]. Therefore, the
primary goal of looking at registry data on rare disorders
such as acquired hemophilia is to generate insights that
can help improve its diagnosis and treatment in the
context of the inability to perform prospective-controlled
trials because of the limited number of patients with
acquired hemophilia. Toward our goal of generating
treatment hypotheses, we sought in this analysis to use
the heterogeneous nature of the US population and the
HTRS Registry to expand the discussion of demographic
contributions to the development and diagnosis of
acquired hemophilia.
Comparing acquired hemophilia registries and
populations
There are methodological differences in assessing demo-
graphics within different acquired hemophilia registries.
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Table 4 Distribution of first bleed locations by sex, race, and ethnicity
All Female Male White Black Non-Hispanic Hispanic
Number of patients, n 166 83 73 117 40 140 17
First bleeding site, n (%)
Subcutaneous 45 (27.1%) 25 (30.1%) 15 (20.5%) 34 (29.1%) 5 (12.5%) 37 (26.4%) 2 (11.8%)
Extremity NOS 12 (7.2%) 4 (4.8%) 8 (11.0%) 9 (7.7%) 2 (5.0%) 9 (6.4%) 2 (11.8%)
Subcutaneous þ extremity NOS 57 (34.3%) 29 (34.9%) 23 (31.5%) 43 (36.8%) 7 (17.5%) 46 (32.8%) 4 (23.6%)
Mucosal 35 (21.1%) 17 (20.5%) 17 (23.3%) 24 (20.5%) 10 (25.0%) 29 (20.7%) 5 (29.4%)
Muscle 9 (5.4%) 2 (2.4%) 5 (6.8%) 8 (6.8%) 1 (2.5%) 7 (5.0%) 2 (11.8%)
Joint 7 (4.2%) 3 (3.6%) 4 (5.5%) 5 (4.3%) 2 (5.0%) 7 (5.0%) 0 (0.0%)
Retroperitoneal 4 (2.4%) 2 (2.4%) 1 (1.4%) 3 (2.6%) 1 (2.5%) 4 (2.9%) 0 (0.0%)
Surgery/biopsy/IV-PICC site 3 (1.8%) 0 (0.0%) 3 (4.1%) 2 (1.7%) 1 (2.5%) 3 (2.1%) 0 (0.0%)
Postpartum 3 (1.8%) 3 (3.6%) NA 3 (2.6%) 0 (0.0%) 3 (2.1%) 0 (0.0%)
Head 3 (1.8%) 3 (3.6%) 0 (0.0%) 3 (2.6%) 0 (0.0%) 2 (1.4%) 1 (5.9%)
Other 7 (4.2%) 6 (7.2%) 1 (1.4%) 3 (2.6%) 4 (10.0%) 7 (5.0%) 0 (0.0%)
Not specified 27 (16.3%) 27 (32.5%) 20 (27.4%) 29 (24.8%) 18 (45.0%) 41 (29.3%) 6 (35.3%)
IV-PICC, intravenous peripherally inserted central catheters; NA, not applicable; NOS, not otherwise specified.Within nationalized healthcare systems or within those
organized around few hemophilia treatment centers
(HTCs), the pattern of patient presentations differs from
that seen in the HTRS Registry population. For the
UKHCDO study, referral was within a centralized net-
work with a high capture rate under a national health
plan. The United Kingdom has 256 hematology depart-
ments; 255 of those departments participated in the
UKHCDO study and reported on 172 patients over
the course of 2 years [2]. The hematology departments
also directly oversee coagulation laboratories and hence
may have earlier information about patients with abnor-
mal aPTT studies. In the French SACHA Registry,Table 5 Distribution of blood product exposure history by race and et
All White




Packed RBC, n (%) 40 (28%) 28 (28%)
Mean (days) 3.7 4.5
Median (days) 2 2
IQR (days) 1–3 1–4
Minimum–maximum (days) 1–43 1–43
Values estimated, n (%) 22 (60%) 17 (60%)
Whole blood or FFP, n (%) 21 (14%) 13 (13%)
Mean (days) 4.2 2.7
Median (days) 2 1
IQR (days) 1–3 1–3
Minimum–maximum (days) 0–40 1–10
Values estimated, n (%) 14 (70%) 8 (60%)
Platelets, n (%) 5 (3%) 2 (2%)
Mean (days) 21.5 2.0
Median (days) 2.5 2
IQR (days) 1.75–22.25 1.5–2.5
Minimum–maximum (days) 1–80 1–3
Values estimated, n (%) 3 (60%) 2 (70%)
Cryoprecipitate, n (%) 2 (1%) 1 (1%)
Mean (days) 10.0 10.0
Median (days) 10 10
Factor 8, n 8 6
Mean 5.0 5.0
Median 2 2
Factor 9, n 1 1
Mean 9.0 9.0
Median 9 9
FFP, fresh frozen plasma; IQR, interquartile range; NA, not applicable; QNS, quantity82 patients were identified over the course of 4 years
[10]. In the larger European study (EACH2), 501 patients
were recruited through 117 HTCs in 13 countries under
informed consent with exceptions; six countries required
informed consent for living patients only, and five
countries did not require informed consent but did not
allow enrollment of patients who were deceased [11,12].
This may have excluded patients who were more
severely affected [11].
The HTRS Registry differs from European registries in
that the underlying system supporting the care of










5 (50%) 19 (50%) 3 (100%)





6 (80%) 10 (60%) 4 (100%)





1 (50%) 1 (30%) 2 (100%)









not specified; RBC, red blood cells.
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is due in part to the way hemophilia care is funded, with
more HTCs and experts available to facilitate the
diagnosis and management of children with congenital
bleeding disorders than adults with acquired disorders.
Further, multispecialty case-based surveys have ident-
ified that physicians who would primarily see a patient
with undiagnosed acquired hemophilia (e.g. emergency
medicine, hospitalists, critical care, rheumatology, obste-
trics/gynecology) are more focused on identifying the
underlying site of bleeding than in appreciating that
the aPTT values are abnormal, or that they might reflect
an underlying bleeding disorder [9]. Given that the US
system encourages the presentation of acquired hemo-
philia in an acute setting, physicians sometimes resist
referring patients to hematology [9]; thus, the lack of
uniform distribution and availability of specialized coagu-
lation expertise become barriers to diagnosis.
The heterogeneity of the US population allows for an
analysis of race and ethnicity as covariates for both the
risk of acquired hemophilia and the likelihood of receiv-
ing the proper diagnosis. Black patients with acquired
hemophilia appear overrepresented (24.1%) compared
with the relative percentage of blacks within the US
population (13.6%) [13]; the 1.8 times higher ratio of
percentage of black patients compared with the total
population suggests that blacks may have a higher risk
of developing acquired hemophilia. Notably, there has
been the suggestion that blacks with hemophilia A have a
higher risk of developing FVIII alloantibody inhibitors as
well. Through the Universal Data Collection Program,
black and Hispanic patients with hemophilia A in the
United States have reported twice the FVIII inhibitor
rate of white patients in the United States [14]. Hemo-
philia A inhibitor formation appears to be more frequent
in African-American patients, and central nervous system
bleeding was seen more frequently as a first bleeding
event in this population [15]. The HTRS data are the first
to suggest that a similar increased risk might exist for
autoantibody FVIII inhibitors. There are some human
leukocyte antigen (HLA) haplotypes identified that
might predispose to autoantibody formation [16], and
perhaps mapping HLA haplotypes may identify racial
differences and predispositions. Hispanic patients appear
somewhat underrepresented (10.2%) compared with
Hispanics in the general US population (16.7%) [17].
However, Hispanic children comprise a much higher
percentage of US children (22% of children aged
<18 years) [18] but comprise a smaller percentage of
the elderly US population (those at risk for acquired
hemophilia), which suggests that Hispanic adults are
not disproportionally affected by acquired hemophilia.
Predisposing conditions
In the initial study by Green and Lechner [1], acquired
hemophilia was commonly associated with malignancy(6.7%) and autoimmune disorders (17.0%). This was
also seen in the UKHCDO study (malignancy, 14.7%;
autoimmune, 16.7%) and EACH2 (malignancy, 11.8%;
autoimmune, 13.4%) [2,5]. In the HTRS Registry, 28.3%
of patients with acquired hemophilia reported an auto-
immune disorder and 14.5% reported malignancy. Once
diabetes (type 2 or unspecified) is excluded as an auto-
immune disorder in HTRS, the percentage of patients
with an autoimmune disorder drops to 18.6% and is more
aligned with previous reports of autoimmune comorbid-
ities in patients with acquired hemophilia. Given the
prevalence of diabetes in the elderly population most
commonly seen with acquired hemophilia, the coinci-
dence of diabetes and acquired hemophilia is of
unclear significance.
In the HTRS Registry, polycythemia vera and myelofi-
brosis were initially reported as ‘other disorders’ but have
been subsequently recategorized as malignancies. Sparse
data on patients with cancer are available from the
European registries; however, in the United States, there
were surprisingly few cases of acute or chronic leukemias.
Three cases of leukemia were reported, two of which
were known by the authors to be chronic
lymphocytic leukemia.
The percentage reporting PPH (3.4%) in the HTRS
Registry is similar to that reported in the UKHCDO
study (2.0%) [2], but lower than that initially reported
by Green and Lechner [1] (7.3%) or that reported in
SACHA (7.3%) [10] or EACH2 (8.4%) [5]. The lower
incidence of PPH in the HTRS Registry may be because
of US obstetricians being hesitant to refer patients to
hematologists [9].
There are no longitudinal data from acquired hemophilia
that extend long enough to determine if acquired hemo-
philia could be a harbinger of future autoimmune disease
or malignancy. Referral patterns and insurance provider
network restrictions within the United States would
make long-term follow-up after successful immunosup-
pression or ITT difficult to accomplish. Anecdotally,
there is some evidence that the recurrence of the
acquired inhibitor is contemporaneous with the recur-
rence of malignancy [19]; this suggests that additional
study might provide more insight into idiopathic
acquired hemophilia.
First bleeding episodes
The HTRS Registry is the first study to examine symp-
toms by race and ethnicity and to show a racial and ethnic
disparity for subcutaneous bleeding episodes, with
whites and non-Hispanics being more likely to have
subcutaneous bleeding as their first bleed site. With other
bleeding disorders, such as immune thrombocytopenic
purpura, some have argued that the data show possible
racial disparities in the overall incidence of the disease,
with blacks having a much lower prevalence than
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authors, after reviewing the Veterans Administration
population, state that this may be because of the fact
that in blacks, the presence of petechiae and ecchymoses
may not be recognized [20,21]. A racial disparity among
other dermatological disorders, such as skin cancer and
atopic dermatitis, is not uncommon [22,23]. In atopic
dermatitis, a reliance on erythema scores may mask the
severity of disease in black children [22].
Blood product exposure
With data in the HTRS Registry and these analyses, it is
assumed that blood product exposure is reported at
registration and is therefore historical. However, this
may not be totally accurate. Transfusion requirements
cannot distinguish between replacement therapy for
bleeding occurring before the diagnosis and treatment
after diagnosis, reflecting the efficacy of the chosen
hemostatic treatment approach. In the HTRS Registry,
the collected data on blood product exposure included
information on packed RBCs, FFP or whole blood,
cryoprecipitate, platelets, and coagulation factors. The
higher percentage of patients exposed and the mean/
median number of days of FFP exposure observed in
blacks and Hispanics may reflect a delay in diagnosis in
those patients with abnormal aPTT values, a lack of
coagulation experts or laboratory capacity to facilitate
diagnostic workup and formulation of a treatment plan,
and/or a lack of availability of bypassing agents for acute
management outside of HTCs.
Immune tolerance/suppression
The data from the HTRS Registry suggest a very high
success rate with immune tolerance induction regimens
for acquired hemophilia in the United States. Our data
entry form for the acquired hemophilia registry offered
‘immune tolerance’ as a treatment option to eradicate the
auto-FVIII neutralizing antibody and did not specify any
choices for how immune tolerance was to be approached.
Thus, there is a possibility that the data collected may
represent a broad array of approaches, including factor
VIII (formal immune tolerance induction regimens),
corticosteroids, cytotoxic agents, intravenous immuno-
globulins, rituximab, and biologic response modifiers.
The high rate of reported successful tolerance in this
acquired hemophilia registry, the precise regimen(s)
employed for best outcome, and the durability of
response need to be confirmed in prospective studies.
Furthermore, in future studies, the increasing use of
rituximab for FVIII autoantibody eradication should be
scrutinized closely and longitudinally as this anti-CD20
monoclonal antibody may convey benefits and potential
adverse effects for those with acquired hemophilia.
For example, rituximab therapy may alter B and
T-lymphocyte numbers, resulting in favorable reduction
of specific autoantibodies directed against FVIII and/or
altering the underlying autoimmune disease process,which was associated with the development of
acquired hemophilia.
Limitations
In registries such as HTRS, the periodic entry (batches)
of patient cases reflects the reality of rare disorder sur-
veillance; however, this may result in missed patients or
missed episodes and may not be truly reflective of the
total number of cases of acquired hemophilia. This also
leads to difficulty in capturing longitudinal data and
especially in the follow-up of patients who become
inactive (e.g. spontaneous remissions, successful treat-
ment of underlying comorbid conditions, successful
immune tolerance, deceased). Although the HTRS Reg-
istry only captures a small percentage of the number of
patients diagnosed with acquired hemophilia in the
United States, the registry has a high rate of capture in
the 36 participating sites. The limited number of sites
may reflect regions in which referral networks are more
structured and where HTCs exist (e.g. Washington,
DC; Philadelphia, Pennsylvania; Chapel Hill, North
Carolina). The HTRS Registry has, for acquired hemo-
philia specifically, missing geographic regions with large
populations of elderly patients (e.g. Florida, Southern
California) where the racial and ethnic population mix,
referral patterns, or availability of adult coagulation
experts may be different. The subset of acquired hemo-
philia-participating sites were predominantly adult
HTCs within the HTRS registry, which at one time
included up to 100 of the 141 federally designated HTCs
in the United States [24]; however, at present, the United
States has approximately 5700 hospitals [8] and 10 200
practicing hematologists and oncologists that could
potentially see a patient [25]. In an attempt to capture
this broader population, the alternative surveillance
acquired hemophilia study collected bleed data from
99 patient cases submitted by 92 centers between 2008
and 2011 [26]. Ultimately, the demographics of those
captured in HTRS are consistent with those of other
acquired hemophilia data sets, suggesting these data are
representative of the acquired hemophilia population in
the United States.
Conclusions
This analysis of the HTRS Registry represents the largest
North American and non-European data set on acquired
hemophilia, and provides the only current, comprehen-
sive demographic look at acquired hemophilia in the US
population. This article provides the first suggestion that
there may be racial and ethnic differences in the risk of
autoantibody FVIII inhibitors, similar to the increased
risk already identified in blacks who develop FVIII
alloantibodies in congenital hemophilia. Such obser-
vations highlight the need for a more complete under-
standing of basic immune response mechanisms and the
development of allo- and autoantibodies, and the role of
Hemostasis and Thrombosis Research Society Registry: Demographics Kessler et al. 769HLA haplotype distributions in different racial and
ethnic groups.
As was seen in the UK patients with acquired
hemophilia [2,3], the HTRS Registry data indicated
that subcutaneous bleeds were the most common
bleeding site reported in patients with acquired
hemophilia. Interestingly, we see that cutaneous bleed-
ing as a presenting bleeding symptom was most
notable in white and non-Hispanic individuals,
suggesting that darker skin color may delay the diag-
nosis of acquired hemophilia. This correlates with a
delay in diagnosis of immune thrombocytopenic
purpura reported in individuals with dark skin
[20,21] and in the diagnosis of other dermatologic
disorders in such patients [22,23].
In summary, the hypothesis generation in this and the
other acquired hemophilia databases should form
the basis of future cooperative and multinational pro-
spective studies that can elucidate specific immuno-
pathophysiologies and factors that influence treatment
decisions. This may ultimately lead to standardized treat-
ment approaches and the identification of groups requir-
ing specific targeted approaches. Comparing US and
European databases identifies the imperfect referral
mechanisms and the increased problems associated with
the lack of rare-disease awareness working in the US
system of heterogeneously distributed HTCs for adult
coagulation disorders.Acknowledgements
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